Interview on Ontada research presented at ISPOR 2024.
Research presented May 6, 2024, at ISPOR—The Professional Society for Health Economics and Outcomes Research highlights the potential for AI generally and natural language processing (NLP) specifically to aid recruitment in clinical trials. A team from Ontada highlighted how use of NLP can be used to identify patients who meet criteria for oncology trials but whose clinical characteristics may not be recorded in structured data of an electronic health record (EHR).
Jessica Paulus, ScD | Image: Ontada
According to the abstract, pretrained NLP models were used to
find patients whose data were contained in the clinical notes of the iKnowMed oncology-specific EHR, used by community oncology practices. Investigators reported that “a randomly selected sample of NLP results were validated by clinical abstractors for each study to ensure accuracy and reliability,” the authors said.
Jessica Paulus, ScD, senior director, observational research for Ontada, who presented the findings and spoke with EBO, said the ability to accurately assess the potential universe of patients eligible for a clinical trial can make or break whether a study proceeds. This is important when “we’re trying to get our arms around how many patients we have for the study because that’s a major limiting factor in terms of the validity or the efficiency, and even the ethics of going forward for the study,” she said.
“If you don’t have enough patients, that can be ethically problematic, even for real-world data, not [just] interventional studies,” Paulus said.
Finding eligible patients in the structured data is often the easy part, she explained. For this project, Ontada researchers applied algorithms for 20 feasibility studies in a variety of disease states, including lymphoma, renal cell carcinoma (RCC), and rectal cancer, to identify eligible patients “hidden” in the notes who could be added to those revealed in the structured data.
“Even though our data [are] on an electronic health record and [are] consistently used across the entire health care system…there can be cases—a fairly abundant number of cases—where oncologists will document a treatment that a patient perceives in their clinical narrative notes, but not necessarily in the code that they’re entering in the drop-down menu,” Paulus explained. Using NLP can allow rapid recovery of this second group of patients and can increase the potential universe of patients eligible for a study by 3.5 times the original number, results show.
The project greatly enhances Ontada’s ongoing work with FDA to use RWD to investigate rare cancers, she said.
Results. NLP algorithms were applied across 20 feasibility studies. In 17 studies, the process expanded the sample size from structured data counts, while in 3 studies, authors reported that the use of NLP reduced the number of patients necessary for manual chart abstraction. When the goal was to increase the sample size, the average boost was 3.5-fold, with a range of 1.1- to 7.4-fold. When the goal was to reduce the sample size for abstraction, the mean reduction was 80% in the number of patients, with a range of 69% to 89%.
Investigators reported “the NLP results demonstrated high validity.” In a study for RCC, the NLP model pinpointed 315 patients who underwent nephrectomy, and 295 (93%) met inclusion criteria during manual chart abstraction. “This offers a scalable solution for conducting RWD studies and supplements high-effort and costly activities like manual chart abstraction,” they concluded.
Reference
Raju A, Doko G, Su Z, Paulus J, Robert NJ. Use of natural language processing to augment real-world data (RWD) and identify eligible patients at scale for oncology studies. Value Health. 2024;27(6):S1,MSR30
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512